DoubleChecks

What was claimed

84% of cancer patients taking ivermectin achieved complete remission, tumor shrinkage, or halted tumor growth according to peer-reviewed data

Our verdict

Inaccurate

The cited peer-reviewed cohort reports an 84.4% 'clinical benefit ratio' for patients taking a combination of ivermectin and mebendazole, defined as complete response, partial response, or stable disease, and based on self-reported outcomes in an uncontrolled, heterogeneous, real-world cohort. This does not demonstrate that 84% of cancer patients taking ivermectin achieve remission, shrinkage, or halted growth, and oncology experts and health systems explicitly state there is currently no evidence in humans that ivermectin decreases cancer growth or is effective for treating cancer, with no clinical trials confirming safety or efficacy as a cancer treatment. While the study was published in a peer-reviewed journal, the authors explicitly state results are 'hypothesis-generating' and call for randomized controlled trials. The observational design with self-reported outcomes and confounding from concurrent conventional treatments significantly limits the strength of evidence.

2 of 3 AI systems agree9 sources citedChecked Jun 29, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

84% of cancer patients taking ivermectin achieved complete remission, tumor shrinkage, or halted tumor growth according to peer-reviewed data

Incorrect93%
2 of 3 AIs agree·Claude: Misleading

This outcome is supported by peer-reviewed data

Misleading90%
1 AI checked

The study measured complete remission, tumor shrinkage, or halted tumor growth

Verified95%
1 AI checked

Verified against 9 sources

youtube.compubmed.ncbi.nlm.nih.govzenodo.orgpmc.ncbi.nlm.nih.govpatientpower.infouclahealth.orgnpr.orginstagram.cominstagram.com

Detailed Analysis

The statement cherry-picks an observational figure and misrepresents it as proof that ivermectin treats cancer. The underlying study is small, non-randomized, self-reported, and combines ivermectin with another drug, so it cannot justify a claim of 84% remission or halted growth from ivermectin in cancer patients. Major cancer and academic sources state there is currently no clinical evidence that ivermectin is effective at decreasing cancer growth in humans.

Why this verdict

  • The statement cherry-picks an observational figure and misrepresents it as proof that ivermectin treats cancer.
  • The underlying study is small, non-randomized, self-reported, and combines ivermectin with another drug, so it cannot justify a claim of 84% remission or halted growth from ivermectin in cancer patients.
  • Major cancer and academic sources state there is currently no clinical evidence that ivermectin is effective at decreasing cancer growth in humans.

Claims checked

84% of cancer patients taking ivermectin achieved complete remission, tumor shrinkage, or halted tumor growth according to peer-reviewed data

Incorrect93%
The cited peer-reviewed cohort reports an 84.4% 'clinical benefit ratio' for patients taking a combination of ivermectin and mebendazole, defined as complete response, partial response, or stable disease, and based on self-reported outcomes in an uncontrolled, heterogeneous, real-world cohort.[2] [3] This does not demonstrate that 84% of cancer patients taking ivermectin achieve remission, shrinkage, or halted growth, and oncology experts and health systems explicitly state there is currently no evidence in humans that ivermectin decreases cancer growth or is effective for treating cancer, with no clinical trials confirming safety or efficacy as a cancer treatment.[4] [5] [6]

This claim may mislead readers without added context.

What other AI think

The 84% figure is technically accurate but highly misleading. The study involved a combination drug (ivermectin + mebendazole), not ivermectin alone. The study was observational with self-reported outcomes, many patients received concurrent conventional treatments, and only 62% completed follow-up. The authors themselves state results are "hypothesis-generating" and call for rigorous randomized trials.

Why this verdict

  • The 84% figure is technically accurate but highly misleading.
  • The study involved a combination drug (ivermectin + mebendazole), not ivermectin alone.
  • The study was observational with self-reported outcomes, many patients received concurrent conventional treatments, and only 62% completed follow-up.
  • The authors themselves state results are "hypothesis-generating" and call for rigorous randomized trials.

Claims checked

This outcome is supported by peer-reviewed data

Misleading90%
While the study was published in a peer-reviewed journal, the authors explicitly state results are 'hypothesis-generating' and call for randomized controlled trials. The observational design with self-reported outcomes and confounding from concurrent conventional treatments significantly limits the strength of evidence.

This claim may mislead readers without added context.

84% of cancer patients taking ivermectin achieved complete remission, tumor shrinkage, or halted tumor growth

Misleading95%
The 84.4% figure exists but refers to a combination of ivermectin AND mebendazole, not ivermectin alone. The claim omits this critical detail and misrepresents the drug being studied.

This claim may mislead readers without added context.

The study measured complete remission, tumor shrinkage, or halted tumor growth

Verified95%
The study did measure these outcomes, though they were self-reported by patients rather than objectively verified through imaging or clinical assessment.
The statement misrepresents the evidence and omits key context. The 84% figure comes from a recent observational cohort reporting an 84.4% 'Clinical Benefit Ratio' for an ivermectin + mebendazole regimen at six months, not a randomized, controlled, peer‑reviewed proof that ivermectin alone causes remission. The study is non‑randomized, largely self‑reported, includes combination therapy and confounding interventions, and has been flagged by fact‑checkers and experts as low‑quality or not a proper clinical trial.

Why this verdict

  • The statement misrepresents the evidence and omits key context.
  • The 84% figure comes from a recent observational cohort reporting an 84.4% 'Clinical Benefit Ratio' for an ivermectin + mebendazole regimen at six months, not a randomized, controlled, peer‑reviewed proof that ivermectin alone causes remission.
  • The study is non‑randomized, largely self‑reported, includes combination therapy and confounding interventions, and has been flagged by fact‑checkers and experts as low‑quality or not a proper clinical trial.

Claims checked

84% of cancer patients taking ivermectin achieved complete remission, tumor shrinkage, or halted tumor growth according to peer-reviewed data

Incorrect92%
The 84.4% figure refers to a recent observational cohort of ivermectin plus mebendazole with self‑reported outcomes at six months, not robust peer‑reviewed evidence that ivermectin alone produces remission; the study is nonrandomized and has major methodological limitations.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks